An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

"Given the Supreme Court's ruling, HHS is now permitted to move forward with a portion of its RIF. Accordingly, you are ...

When we think about treating bipolar I disorder (BD-I), the conversation often starts with pharmacotherapy as medication ...

From insulin to immunotherapies, clinical trials have powered some of the most important medical breakthroughs of our time.

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Sidders discusses how integrating causality in AI for biotechnology can drive greater R&D success, and more generally about ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

The UK Biobank has completed the world's largest whole body imaging project, compiling more than a billion scans from 100,000 ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...